Company Encyclopedia
View More
name
TRANSTHERA-B
02617.HK
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc.
1.391 T
02617.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | TRANSTHERA-B faces pressure and rebounds again, will there be opportunities after short-term divergence?

    TRANSTHERA-B (2617.HK) has recently encountered some pressure at high levels after a continuous rebound. Observing from the daily chart, the stock price has approached previous highs multiple times but has failed to break through effectively, followed by a pullback. However, the recent MACD indicator has formed a golden cross, and the trading volume has not significantly shrunk, indicating a strong willingness of the main funds to support the stock. The short-term decline is more of an adjustment due to digestion of previous gains and loosening of high-level shares. In the early trading session, the stock price found support after pulling back to the 5-day moving average and rebounded slightly, showing that some funds are taking action at key positions. Currently, there is a significant divergence between bulls and bears, but signs of bottom funds protecting the stock are quite evident. If the subsequent pullback on reduced volume does not break below the 10-day moving average and is accompanied by an increase in trading volume, the market is expected to challenge the high-pressure zone again. Conversely, if there is a weak rebound on reduced volume and a worsening divergence between price and volume, caution should be taken regarding the risk of a pullback due to short-term overbought pressure. Overall, although TRANSTHERA is currently in a bullish trend, whether it can break through still requires attention to changes in trading volume and main fund movements after the divergence. It is recommended to pay attention to intraday fluctuations and the gains and losses of key support levels, and to manage positions and stop-losses effectively

    Technical Forecast·
    HK
    02617
    -4.84%
    Technical Forecast·
    HK
    02617
    -4.84%

    Hong Kong Stock Movement: TRANSTHERA-B rises 17.13%, $881.5 million cooperation agreement ignites market enthusiasm

    TRANSTHERA-B rose 17.13%; CanSino Biologics rose 2.52%, with a transaction volume of HKD 1.003 billion; Innovent Biologics rose 0.92%, with a transaction volume of HKD 792 million; 3SBio rose 0.87%, with a transaction volume of HKD 600 million; BeiGene rose 0.60%, with a market capitalization of HKD 284.9 billion

    HK Stock Movers Tracker·
    HK
    02617
    -4.84%
    HK Stock Movers Tracker·
    HK
    02617
    -4.84%

    Understanding the Market | TRANSTHERA-B opened over 6% higher after reaching a project cooperation agreement with Neurocrine to further develop NLRP3-related technologies

    TRANSTHERA-B's stock price opened more than 6% higher, and as of the time of writing, it has risen 6.58% to HKD 195.9, with a trading volume of HKD 6.5627 million. The company has signed a patent transfer and research cooperation agreement with Neurocrine Biosciences to develop NLRP3 inhibitors, with a total potential value of USD 881.5 million, covering exclusive development rights and related research cooperation outside of Greater China

    Zhitong·
    HK
    02617
    -4.84%
    Zhitong·
    HK
    02617
    -4.84%

    Hong Kong stock movement: TRANSTHERA-B rose 12.10%, with active capital flow, raising market attention on sector trends?

    TRANSTHERA-B rose 12.10%; 3SBio rose 10.62%, with a transaction volume reaching HKD 1.202 billion; Innovent Biologics rose 6.88%, with a transaction volume reaching HKD 973 million; CanSino Biologics rose 3.16%, with a transaction volume reaching HKD 626 million; BeiGene rose 2.27%, with a market value reaching HKD 291.8 billion

    HK Stock Movers Tracker·
    HK
    02617
    -4.84%
    HK Stock Movers Tracker·
    HK
    02617
    -4.84%

    Hong Kong stock movement: TRANSTHERA-B stock price soared 12.85%, domestic stock conversion to H shares plan ignites market enthusiasm

    TRANSTHERA-B rose 12.85%; Innovent Biologics fell 0.17%, with a transaction volume of HKD 5.124 billion; CanSino Biologics fell 2.34%, with a transaction volume of HKD 770 million; Rongchang Biologics fell 3.22%, with a transaction volume of HKD 515 million; BeiGene fell 2.68%, with a market value of HKD 285.3 billion

    HK Stock Movers Tracker·
    HK
    02617
    -4.84%
    HK Stock Movers Tracker·
    HK
    02617
    -4.84%